Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 89% confidence The document is a SEC Form 8-K “Current Report” filed pursuant to the Exchange Act, reporting an “Other Events” update (presentation of clinical data and exhibits). It does not contain full financial statements or constitute an earnings release, management change, proxy, dividend, or any of the specialized report types. It is a general regulatory filing and therefore falls under the fallback category Regulatory Filings (RNS).
2026-05-26 English
8-K
Regulatory Filings Classification · 91% confidence The document is a U.S. SEC Form 8-K “Current Report” filing reporting an “Other Events” press release. It does not present financial statements, management discussion, or other specialized content categories (e.g., earnings release, capital update, M&A, etc.). It is a generic regulatory compliance filing and thus falls under the fallback category for miscellaneous regulatory announcements. Accordingly, it is classified as Regulatory Filings (RNS).
2026-05-19 English
8-K
Regulatory Filings Classification · 87% confidence The document is a U.S. SEC Form 8-K “Current Report” filed under the Securities Exchange Act of 1934, providing a disclosure of “Other Events” (press release presentation) and listing exhibits. It does not contain financial statements itself nor announce voting results, M&A, dividends, or management changes. It is a standard regulatory filing, so falls into the fallback category for general compliance and reporting notifications: Regulatory Filings (RNS).
2026-05-18 English
8-K - Lipocine Inc. (0001535955) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 8-K (“Current Report”) filed under the Securities Exchange Act containing Item 2.02 (Results of Operations and Financial Condition) and a reference to a press release as Exhibit 99.1. It does not itself include the financial statements or detailed earnings figures, but rather furnishes a press release in a regulatory filing format. There is no standalone earnings narrative in the text, and it is not the full quarterly report, but a compliance filing. The closest category for this Form 8-K filing is Regulatory Filings (RNS).
2026-05-07 English
10-Q - Lipocine Inc. (0001535955) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
DEF 14A - Lipocine Inc. (0001535955) (Filer)
Proxy Solicitation & Information Statement
2026-04-21 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.